<DOC>
	<DOC>NCT00826020</DOC>
	<brief_summary>The purpose of this study is to determine if established parenteral nutrition (PN) associated liver disease can be reversed or its progression halted by using a parenteral fat emulsion prepared from fish oil as measured by normalization of serum levels of hepatic enzymes and bilirubin.</brief_summary>
	<brief_title>Evaluation of Omegaven™ Parenteral Nutrition in Patients With TPN-Induced Cholestasis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Patients must be enrolled in the Intestinal Rehabilitation Program at the University of Nebraska Medical Center, AND: Be unable to meet nutritional needs solely by enteral nutrition and be expected to require PN for at least another 30 days Have clinical evidence of parenteral nutrition associated liver disease (PNALD) as defined as a direct bilirubin of 2 mg/dl or more. A liver biopsy is desirable but not necessary for treatment Signed patient informed consent Parent or guardian or child unwilling to provide consent or assent Inability or unwillingness on the part of parent/guardian or child to follow clinical recommendations of the Intestinal Rehabilitation Program Allergies or clinical conditions precluding safe use of Omegaven™</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>PN</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>fat emulsions</keyword>
	<keyword>omega-6 fatty acid</keyword>
	<keyword>liver disease</keyword>
	<keyword>fatty acid deficiency</keyword>
</DOC>